In another gene therapy example, siRNA lipid nanoparticles (ND‐L02‐s0201) are being studied in clinical trials to downregulate procollagen synthesis, for the treatment of hepatic fibrosis.83 Alnylam is continuing their previously published work on a liposomal siRNA therapeutic for the treatment of Transthyretin (TTR)‐mediated amyloidosis by targeting knockdown of the TTR protein. Here, TTR is linked to amyloidosis.